Targeting tumors with iodine-123 labeled deoxyuridine: distribution and DNA binding.
Publication/Presentation Date
1-1-1999
Abstract
5-lodo-2'-deoxyuridine (IUdR), a thymidine analog, is transported through cell membrane and is incorporated into newly synthesized DNA during the S phase of mitotic cells. In rapidly growing brain tumors such as glioma, radioiodinated IUdR may be an efficient diagnostic as well as therapeutic agent and may provide a means to determine the proliferative activity of the tumor. IUdR was labeled with 123I (t1/2 = 13.3 h, gamma = 159 KeV, 83%) and injected i.v. into nude mice bearing human colorectal carcinoma LS174T. At 3 and 20 h postinjection, tumor uptake was 2.6 +/- 0.9% and 0.5 +/- 0.2%, respectively, of the injected dose per gram of tissue. Radioactivity in other tissues also declined as a function of time, but much more rapidly, yielding tumor-to-blood ratios of 16.4 +/- 2.2 and tumor-to-muscle ratios of 22.2 +/- 7.7 at 20 h postinjection. Of the radioactivity in the tumor, 12.6 +/- 0.9% was bound to DNA at 3 h and 25.2 +/- 2% at 20 h postinjection. A high (7 +/- 1.1% i.d.) uptake in thyroid at 3 h postinjection indicated dehalogenation in vivo.
Volume
23
Issue
1
First Page
72
Last Page
77
ISSN
0361-090X
Published In/Presented At
Thakur, M. L., Li, J., Kim, S. M., Zhang, J. J., & Andrews, D. (1999). Targeting tumors with iodine-123 labeled deoxyuridine: distribution and DNA binding. Cancer detection and prevention, 23(1), 72–77. https://doi.org/10.1046/j.1525-1500.1999.00068.x
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
9892993
Department(s)
Administration and Leadership
Document Type
Article